Verge Genomics Halts ALS Drug Development After Clinical Failure, Refocuses on AI Platform
Verge Genomics
Developer of Neurodegenerative Disease Therapies
Verge Genomics, once a highly anticipated AI drug discovery company, has announced its decision to halt the development of its only clinical-stage candidate drug, VRG50635, and return to its original focus on AI-driven drug discovery.
This significant decision was made after the drug (targeting Amyotrophic Lateral Sclerosis, or ALS) failed to pass the pre-specified efficacy analysis in Phase 1 clinical trials, which were terminated due to "lack of risk-benefit data."
This move has left Verge's previously reached overseas licensing agreement with Spanish pharmaceutical company Ferrer, valued at approximately $122 million, in limbo. Despite the clinical setback, Verge still plans to achieve "sustainable profitability" by streamlining its cost structure and continuing to invest in its technology platform. The company will also shift its focus towards leveraging its accumulated large-scale human multimodal datasets to empower partners and improve pipeline success rates across the industry.
Looking back at this collaboration, in March 2024, Ferrer expressed high hopes for Verge Genomics' AI neuroscience R&D efforts, signing an agreement to acquire the development and commercialization rights of VRG50635 outside the United States (including Europe, Central and South America, Southeast Asia, and Japan). At that time, this deal was seen as another significant recognition of the value of Verge's CONVERGE® platform, which aims to identify new targets for complex diseases and rapidly translate them into clinical applications.
Prior to this, Verge Genomics had already attracted the favor of several pharmaceutical giants, including a $42 million R&D collaboration with AstraZeneca, and high-value agreements signed with Eli Lilly and Merck in 2021. The foundation of these collaborations lies in Verge’s unique end-to-end digital biotechnology system, which aims to address the continuously rising costs in the biopharmaceutical field and overcome the challenge of biological complexity through technological innovation.
Verge's core competitive advantage lies in its CONVERGE® discovery platform, a closed-loop machine learning system that combines industry-leading proprietary human genomics with advanced computational tools. The platform not only processes up to 61.7 TB of human gene expression data, over 2 million protein interactions, and tens of millions of physiological measurements, but its central strategy is also "human-centric."
Since animal and cell models often fail to accurately predict drug behavior in humans, Verge Genomics conducts research directly using human brain tissue from patients. Targets revealed by this method are claimed to be three times more likely to succeed in clinical trials compared to traditional approaches.
Verge Genomics will now rely on its vast bio-validation data (including 21 TB of cell imaging data and 47 TB of cell omics data) as well as preclinical programs targeting diseases such as Parkinson's disease, schizophrenia, and frontotemporal dementia to continue demonstrating the value of its platform.
This shift from drug development back to technology platforms illustrates,Even with the most advanced AI technology, the risks in drug development remain enormous.
Warm Tips
